Compare

Semnur Pharmaceuticals, Inc. vs Aspire Biopharma Holdings, Inc. vs Accustem Sciences Inc. vs NeuroSense Therapeutics Ltd.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearSemnur Pharmaceuticals, Inc.
SMNR
Aspire Biopharma Holdings, Inc.
ASBP
Accustem Sciences Inc.
ACUT
NeuroSense Therapeutics Ltd.
NRSN
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenuen/a$6.2Kn/an/a
Revenue growth (YoY)n/an/an/an/a
Gross marginn/a-1.9%n/an/a
Operating marginn/an/mn/an/a
Net marginn/an/mn/an/a
Net income-$160.42M-$24.48M-$1.76M-$11.12M
EPS (Diluted)-$0.78-$16.38-$0.12-$0.44
Operating cash flow-$5.87M-$4.92M-$850.4K-$7.67M
Free cash flown/an/an/a-$7.68M
Cash & equivalents$20.0Kn/an/a$166.0K
Total assets$1.35M$1.31M$1.55M$1.03M
Total liabilities$22.10M$7.69M$4.95M$2.59M
Shareholders' equity-$20.75M-$6.38M-$3.40M-$1.56M
Return on year-end equityn/an/an/an/a
Shares outstanding230.21M3.53M16.07M32.56M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearSemnur Pharmaceuticals, Inc.Aspire Biopharma Holdings, Inc.Accustem Sciences Inc.NeuroSense Therapeutics Ltd.
Latestn/a$6.2K
Ended 2025-12-31
n/an/a
1 year earliern/an/an/an/a
2 years earliern/an/an/an/a
3 years earliern/an/an/an/a
4 years earliern/an/an/an/a